42 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26753814	7	Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaVß3 anda5ß1 integrin ligands.	University Of Florence
24949551	22	Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.	Philipps-Universit£T Marburg
24973662	8	Targeting integrinsavß3 anda5ß1 with newß-lactam derivatives.	University Of Bologna
24654918	19	Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.	Technische Universit£T M£Nchen
24900800	46	Small Macrocycles As Highly Active Integrin?2?1 Antagonists.	Sanofi R & D
24095096	3	Synthesis and in vitro evaluation of a novel radioligand foravß3 integrin receptor imaging: [18F]FPPA-c(RGDfK).	University Hospital Of Geneva
23811088	26	Modulation ofavß3- anda5ß1-integrin-mediated adhesion by dehydro-ß-amino acids containing peptidomimetics.	University Of Bologna
23562062	4	Arylsulfonamide pyrimidines as VLA-4 antagonists.	Elan Pharmaceuticals
23362923	59	Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.	Technische Universit£T M£Nchen
19959360	50	SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.	Jerini
19910191	46	Discovery of orally available integrin alpha5beta1 antagonists.	Jerini
7650686	3	Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.	Merck Research Laboratories
22575869	61	Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.	Astrazeneca
22572578	124	Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.	Astrazeneca
20055426	30	Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.	Universita Degli Studi Di Bologna
18331794	20	Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.	Millennium Pharmaceuticals
18303826	48	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.	Universit£
15357991	20	Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.	3-Dimensional Pharmaceuticals
12139455	78	Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.	Genentech
9191954	9	Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.	Merck Research Laboratories
20172716	3	Ultrasmall particle of iron oxide--RGD peptidomimetic conjugate: synthesis and characterisation.	Universit£
17973471	24	Multiple N-methylation by a designed approach enhances receptor selectivity.	Technische UniversitäT MüNchen
17869121	32	Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.	Università
17616113	63	Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.	Jerini
15974570	30	Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.	Università
15715463	16	Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.	Johnson And Johnson Pharmaceutical Research & Development
15109641	4	Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.	Riken Discovery Research Institute
14741263	67	Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.	Nerviano
14698164	39	Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.	Pharmaceutical Research Institute
12852971	8	Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide.	Kyowa Hakko Kogyo
12699755	4	Nonpeptide RGD antagonists: a novel class of mimetics, the 5,8-disubstituted 1-azabicyclo[5.2.0]nonan-2-one lactam.	University Of Montpellier
12565960	33	Thiophene-based vitronectin receptor antagonists.	Shire Biochem
11677134	42	Design and synthesis of potent and selective inhibitors of integrin VLA-4.	Novartis Institute For Biomedical Research
11327582	23	2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.	Taisho Pharmaceutical
10853677	34	Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.	Celltech Chiroscience
10072689	39	Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.	Biogen
9016328	19	Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.	Dupont Pharmaceuticals
8057299	66	Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.	Merck Research Laboratories
7507165	139	Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.	Telios Pharmaceuticals
1469694	22	Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.	Merck Research Laboratories
17915848	48	Small molecule inhibitors of integrin alpha2beta1.	University Of Pennsylvania